Strategic partnership Hager Biosciences specializes in preclinical-stage drug discovery with a focus on out-licensing therapeutic leads for unmet medical needs, presenting a clear pathway for collaboration with pharma and biotech companies seeking early-stage innovative chemistry capabilities.

Fragment-based platform The FragPhore platform enables rapid lead generation and optimization through modular fragment swaps, offering a differentiated value proposition for partners looking to accelerate CNS drug discovery and intellectual property growth.

CNS focus With shown track records and patent activity in CNS programs including Alzheimer’s assets advancing toward clinical trials, there is a compelling signal for engaging target-focused programs in neurology and neurodegenerative diseases.

Patent and IP leverage A robust and expanding patent portfolio around novel small molecules provides potential license-in or collaboration opportunities for partners seeking freedom-to-operate advantages and strong IP positions.

Early-stage alignment Low employee count and preclinical-stage positioning suggest opportunities to engage early, cost-efficient drug discovery partnerships, offering flexible engagement models and rapid proof-of-concept for potential sponsors.